CERT vs CRL

For growth investors, Certara, Inc.

(CERT) is the stronger pick with 8. 7% revenue growth year-over-year, versus -0. 9% for Charles River Laboratories International, Inc. (CRL). Analysts rate Certara, Inc. (CERT) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Charles River Laboratories International, Inc.

(CRL) delivered a total return of -46. 0%, compared to -78. 7% for Certara, Inc. (CERT). Over 10 years, the gap is even starker: CRL returned +124. 7% versus CERT's -83. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Certara, Inc.

(CERT) is the lower-risk stock at 1. 21β versus Charles River Laboratories International, Inc. 's 1. 52β — meaning CRL is approximately 25% more volatile than CERT relative to the S&P 500. On balance sheet safety, Certara, Inc. (CERT) carries a lower debt/equity ratio of 1% versus 95% for Charles River Laboratories International, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Certara, Inc.

(CERT) is pulling ahead at 8. 7% versus -0. 9% for Charles River Laboratories International, Inc. (CRL). On earnings-per-share growth, the picture is similar: Certara, Inc. grew EPS 86. 7% year-over-year, compared to -1555. 0% for Charles River Laboratories International, Inc.. Over a 3-year CAGR, CERT leads at 7. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Certara, Inc.

(CERT) is the more profitable company, earning -0. 4% net margin versus -3. 6% for Charles River Laboratories International, Inc. — meaning it keeps -0. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CRL leads at 12. 6% versus 5. 0% for CERT. At the gross margin level — before operating expenses — CERT leads at 61. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Certara, Inc.

(CERT) trades at 14. 0x forward P/E versus 16. 4x for Charles River Laboratories International, Inc. — 2. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for CERT: 59. 7% to $10. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Certara, Inc.

(CERT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 21)). Charles River Laboratories International, Inc. (CRL) carries a higher beta of 1. 52 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CERT: -83. 6%, CRL: +124. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.